{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2008"],"condition":["Metastatic colorectal adenocarcinoma with metastases involving the liver only","Colorectal cancer stage IV"],"disease":["Metastatic Colorectal Adenocarcinoma With Metastases Involving The Liver Only","Colorectal Cancer Stage Iv"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2518384"],"location":["United Kingdom"],"study_start_month":["5"],"keyword":["Raltitrexed","Xeloda","Eloxatin","Avastin"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer","description":"Primary objectives: To evaluate the response rate of patients with previously untreated unresectable liver-only metastases from colorectal cancer treated with neoadjuvant capecitabine and oxaliplatin plus bevacizumab.\nPrimary endpoints: Overall response rate according to RECIST criteria.","dates":{"creation":"2008-05-15"},"accession":"2518384","cross_references":{"EU Clinical Trials Register":["2005-004505-29"]}}